FDA pans Merck's new pain pill

The U.S. Food and Drug Administration has rejected Merck's bid to sell the pain medication Arcoxia in the United States.

The New York Times says Arcoxia is a sister to Vioxx, which Merck pulled from the market in 2004 after a study showed it increased the risks of heart attacks and strokes.

Arcoxia, currently sold in 63 countries, caused nearly three times as many heart attacks, strokes and deaths as naproxen, which is sold as Aleve, and is about just as effective at reducing pain in arthritis patients. Patients taking Arcoxia also suffered increased blood pressure, the newspaper said.

"What you're talking about is a potential public health disaster," Dr. David Graham, an FDA safety officer, told the panel.

The company said it was "disappointed" in the FDA's rejection.

"We continue to believe that Arcoxia has the potential to become a valuable treatment option for many Americans suffering from osteoarthritis," Merck Research Laboratories President Peter Kim said in a release.

Merck will continue to sell the drug outside the United States, the newspaper said.

Copyright 2007 by United Press International


Explore further

Anti-inflammatory drugs interfere with aspirin's clotting ability

Citation: FDA pans Merck's new pain pill (2007, April 13) retrieved 2 August 2021 from https://medicalxpress.com/news/2007-04-fda-pans-merck-pain-pill.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments